

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON MARCH 31, 2021

Amount in INR Million

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020
		Audited (Refer note 7)	Unaudited	Audited (Refer note 7)	Audited	Audited
	Income					
1	Revenue from Operations	631.58	528.18	414.32	2,084.77	1,694.25
2	Other Income	1.20	6.35	2.97	16.48	29.27
3	Total Income	632.78	534.53	417.29	2,101.25	1,723.52
4	Expenses					
	(a) Cost of material consumed	91.32	53.49	54.01	241.75	276.23
	(b) Purchases of stock-in-trade	80.31	84.22	46.05	252.09	171.89
	(c) Change in inventories of finished goods, traded goods and work in progress	27.50	(34.24)	(49.76)	40.14	(155.74)
	(d) Employee benefits expense	97.87	86.38	109.39	334.51	371.56
	(e) Finance cost	4.72	9.38	17.75	39.47	50.34
	(f) Depreciation and amortisation expense	24.46	24.36	22.86	96.33	93.85
	(g) Other expenses	128.43	132.49	151.98	496.35	503.10
	Total Expenses	454.61	356.08	352.27	1,500.64	1,311.23
5	Profit Before Tax and Exceptional Items	178.17	178.45	65.01	600.61	412.29
6	Exceptional Items (Refer Note 2)	(52.78)	-	-	(52.78)	-
7	Profit before tax	125.40	178.45	65.01	547.83	412.29
8	Tax Expense					
	Current tax	49.78	46.57	20.02	163.65	118.05
	Deffered tax	(12.97)	(1.03)	(5.04)	(14.83)	(18.00)
	Total Tax Expense	36.81	45.54	14.98	148.82	100.05
9	Profit After Tax	88.59	132.91	50.03	399.01	312.24
10	Other Comprehensive Income					
	Items that will not be reclassified to Profit or Loss					
	Remesurement Gain/(Loss) on Defined Benefit Plans	0.01	0.95	0.46	2.86	(5.36)
	Income Tax Impact	(0.00)	(0.24)	(0.12)	(0.72)	1.35
	Total Other Comprehensive Income	0.01	0.71	0.35	2.14	(4.01)
11	Total Comprehensive Income for the period	88.60	133.62	50.37	401.15	308.23
12	Paid-up equity share capital				85.07	85.07
13	Other Equity				2,290.74	1,945.73
14	Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR)	10.41	15.62	5.88	46.90	36.70

STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITIES AS AT 31 MARCH 2021

Amount in INR Million

Particulars	As at 31-03-2021	As at 31-03-2020
I. ASSETS		
(1) Non-current assets		
(a) Property Plant & Equipment	863.07	960.81
(b) Capital Work-in-Progress	35.38	8.74
(c) Other Intangible Assets	3.30	3.93
(d) Biological Assets other than the Bearer Plants	0.56	2.90
(e) Financial Assets		
(i) Investments	438.85	406.71
(ii) Loans	7.40	50.86
(iii) Other Financial Assets	41.14	52.37
(f) Other Non-current Assets	34.39	53.77
	1,424.09	1,540.09
(2) Current assets		
(a) Inventories	570.12	604.32
(b) Financial Assets		
(i) Trade Receivables	455.50	447.61
(ii) Cash and Cash Equivalents	12.44	51.90
(iii) Other Financial Assets	4.17	3.99
(iv) Loans	179.99	0.97
(c) Other Current Assets	173.84	123.02
	1,396.06	1,231.81
Total Assets	2,820.15	2,771.90
II. EQUITY AND LIABILITIES		
(1) Equity		
(a) Share capital	85.07	85.07
(b) Other equity	2,290.74	1,945.73
	2,375.81	2,030.80
(2) Liabilities		
(a) Non-current liabilities		
(i) Financial Liabilities		
-Borrowings	26.76	74.45
-Other Financial Liabilities	3.03	1.53
(ii) Deferred Tax Liabilities (Net)	68.06	82.89
	97.85	158.87
(b) Current liabilities		
(i) Financial Liabilities		
-Borrowings	17.10	318.01
-Trade Payables		
-Total outstanding dues of micro enterprises and small enterprises	2.98	7.08
-Total outstanding dues of creditors other than micro enterprises and small enterprises	137.27	129.00
-Other Financial Liabilities	124.22	98.35
(ii) Other Current Liabilities	26.83	25.38
(iii) Current Tax Liabilities	29.42	-
(iv) Provisions	8.67	4.41
	346.49	582.23
Total Liabilities	444.34	741.10
Total Equity and Liabilities	2,820.15	2,771.90

STATEMENT OF AUDITED STANDALONE CASH FLOWS FOR THE YEAR ENDED ON 31 MARCH 2021

Amount in INR Million

Particulars	Year Ended	
	31-03-2021	31-03-2020
	Audited	Audited
A. Cash Flow from Operating Activities		
Profit Before Tax	547.83	412.29
Adjustments For:		
Depreciation and Amortisation Expense	96.33	93.85
Exceptional Items	52.78	-
Provision for doubtful debt	2.87	-
Bad Debts Written off	6.90	0.62
(Profit) / Loss on Sale of Property, Plant & Equipments	2.69	(4.74)
Interest expense	37.15	38.18
Interest Income	(12.94)	(5.40)
Operating Profit Before Changes in Working Capital	733.61	534.80
Adjustments For:		
Trade Receivables	(17.65)	(121.52)
Inventories	34.20	(119.36)
Other Assets	(50.77)	17.14
Trade Payables	4.17	55.59
Other Current Liabilities	2.94	15.28
Short-term Provisions	4.25	1.19
Loans	(179.03)	1.61
Other Financial Liability	0.44	0.57
Other Financial Assets	3.44	(13.55)
Cash Generated From Operations	535.60	371.74
Income Tax paid (net)	(134.89)	(113.52)
Net Cash Flow from Operating Activities (A)	400.71	258.22
B. Cash Flow from Investing Activities		
Capital Expenditure on Property, Plant & Equipment	(42.50)	(84.00)
Proceeds from sale of Property, Plant & Equipment	0.42	9.81
Investment in Subsidiary Companies	(8.25)	(124.52)
Proceeds from loans repaid	-	3.82
Interest received	12.67	4.43
Investment in Bank Deposits (net)	10.74	(22.87)
Net Cash Flow used in Investing Activities (B)	(26.92)	(213.32)
C. Cash Flow from Financing Activities		
Repayment of long term borrowings	(19.04)	(12.60)
Proceeds/(Repayment) of Short-term Borrowings (net)	(300.91)	108.64
Interest Paid	(37.15)	(38.18)
Dividend Paid (Including Dividend Distribution Tax)	(56.15)	(71.79)
Net Cash Flow used in Financing Activities (C)	(413.25)	(13.92)
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	(39.46)	30.98
Cash and Cash Equivalents at the beginning of the year	51.90	20.92
Cash and Cash Equivalents at the end of the year	12.44	51.90

Notes:

- The above standalone financial results of Hester Biosciences Limited (the "Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 8 June 2021.

- Exceptional items includes:

Particulars	Amount (INR in million)
Loss on disposal of Patan Farm	33.21
Impairment of interest accrued / loan to subsidiary	19.57
Total	52.78

- Followings are the details of segment wise revenue, results, segment assets and liabilities:

(Amount in INR Million)

Particulars	Quarter Ended			Year Ended	
	31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020
Segment Revenue					
a. Poultry Healthcare	485.49	414.53	313.31	1,558.58	1,269.38
b. Animal Healthcare	146.09	113.65	101.02	526.19	424.87
Total	631.58	528.18	414.32	2,084.77	1,694.25
Segment Results					
a. Poultry Healthcare	120.54	140.04	29.54	388.39	310.61
b. Animal Healthcare	27.84	41.45	50.26	201.89	122.75
Total	148.38	181.49	79.80	590.28	433.36
Finance Costs	4.72	9.38	17.75	39.47	50.34
Other unallocated expenditure/ (income) (net)	18.26	(6.35)	(2.96)	2.98	(29.27)
Profit before Tax	125.40	178.45	65.01	547.83	412.29
Segment Assets					
a. Poultry Healthcare	1,822.52	1,758.82	2,009.42	1,822.52	2,009.42
b. Animal Healthcare	325.89	287.29	247.17	325.89	247.17
Unallocated Assets	671.73	819.21	515.33	671.73	515.33
Total	2,820.15	2,865.32	2,771.91	2,820.15	2,771.91
Segment Liabilities					
a. Poultry Healthcare	143.64	278.89	132.31	143.64	132.31
b. Animal Healthcare	39.59	42.98	42.49	39.59	42.49
Unallocated Liabilities	261.10	256.25	566.31	261.10	566.31
Total	444.34	578.11	741.11	444.34	741.11

- During the quarter, the Company has made investment aggregating to INR 23.90 million in the equity shares of its subsidiary, Hester Biosciences Nepal Private Limited.
- The Board of Directors has recommended a dividend of INR 10 per equity share (100%) for FY21, subject to the approval of the shareholders in the ensuing Annual General Meeting.

6. The Code on Social Security, 2020 ("Code") relating to employees benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/ interpretation have not yet been issued. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
7. The figures for the last quarters are the balancing figures between the audited figures in respect of the full year ending 31 March 2021 and 31 March 2020 and the unaudited published year-to-date figures up to 31 December 2020 and 31 December 2019 respectively, being the date of the end of the third quarter of the respective financial years which were subjected to limited review.
8. The figures for the previous year/periods have been regrouped/reclassified wherever necessary to make them comparable to current year/period.

For and on behalf of the Board of Directors



Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

Place: Ahmedabad
Date: 08.06.2021



Hester Biosciences Limited
Head Office
 Pushpak, 1st Floor
 Panchvati Circle
 Motilal Hirabhai Road
 Ahmedabad 380006
 Gujarat, India
 Phone +9179 26445106

Plant Address
 Village Merda-Ardraj
 Taluka Kadi
 District Mehsana
 Gujarat 382721, India
 Phone +9179 26445105

Email mail@hester.in
Toll Free 1800 233 7937
www.hester.in
CIN L99999GJ1987PLC022333

AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31 MARCH 2021

Amount in INR Million

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020
		Audited (Refer note 6)	Unaudited	Audited (Refer note 6)	Audited	Audited
	Income					
1	Revenue from Operations	641.75	568.94	436.20	2,143.32	1,832.68
2	Other Income	24.76	12.71	47.92	46.84	63.66
3	Total Income	666.51	581.66	484.12	2,190.16	1,896.35
4	Expenses					
	(a) Cost of Materials Consumed	142.47	136.99	62.19	386.59	376.33
	(b) Purchase of Stock-in-Trade	22.39	28.14	22.34	79.67	65.16
	(c) Change in inventories of finished goods, traded goods and work in progress	11.69	(28.36)	(55.98)	35.97	(161.68)
	(d) Employee Benefit Expense	111.45	107.91	124.13	389.23	406.51
	(e) Finance Cost	14.35	15.23	25.42	66.04	73.70
	(f) Depreciation and Amortisation Expense	36.30	32.66	31.98	133.14	130.72
	(g) Other Expenses	155.98	112.49	211.64	565.29	592.32
	Total Expenses	494.63	405.06	421.71	1,655.92	1,483.09
5	Profit Before Tax and Exceptional Items	171.87	176.60	62.41	534.24	413.26
6	Exceptional Items (Refer Note 2)	(33.21)	-	-	(33.21)	-
	Profit before tax	138.66	176.60	62.41	501.03	413.26
7	Tax Expense					
	Current tax	51.86	48.35	20.27	169.47	121.67
	Deferred tax	(14.17)	(0.44)	(5.47)	(15.42)	(18.43)
	Total Tax Expense	37.69	47.91	14.81	154.05	103.24
8	Profit After Tax	100.97	128.69	47.60	346.98	310.02
9	Other Comprehensive Income					
	Items that will not be reclassified to Profit or Loss					
	Remesurement Gain/(Loss) on Defined Benefit Plans	0.01	0.95	0.46	2.86	(5.36)
	Income Tax Impact	(0.00)	(0.24)	(0.12)	(0.72)	1.35
	Items that will be reclassified to Profit or Loss					
	Foreign Currency Translation Reserve	(17.59)	(18.18)	20.63	(17.94)	24.49
	Income Tax Impact	-	-	-	-	-
	Total Other Comprehensive Income	(17.58)	(17.47)	20.97	(15.80)	20.48
10	Total Comprehensive Income for the period	83.39	111.21	68.57	331.18	330.50
11	Profit for the period attributable to:					
	(i) Owners of the Company	96.89	123.45	27.41	344.30	291.71
	(ii) Non Controlling Interest	4.08	5.24	20.20	2.68	18.32
12	Other Comprehensive Income for the peiod attributable to:					
	(i) Owners of the Company	(3.50)	(18.54)	20.97	(15.80)	20.48
	(ii) Non Controlling Interest	(14.08)	1.07	-	-	-
13	Total Comprehensive Income for the peiod attributable to:					
	(i) Owners of the Company	93.39	104.91	48.38	328.50	312.19
	(ii) Non Controlling Interest	(10.00)	6.30	20.20	2.68	18.32
14	Paid-up equity share capital (face value of INR 10)				85.07	85.07
15	Reserve as shown in the Audited Balance Sheet of the previous year				2,198.01	1,925.65
16	Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR)	11.87	15.13	5.60	40.79	36.44

STATEMENT OF AUDITED CONSOLIDATED ASSETS AND LIABILITIES AS AT 31 MARCH		
Amount in INR Million		
Particulars	As at 31-03-2021	As at 31-03-2020
I. ASSETS		
(1) Non-current assets		
(a) Property, Plant & Equipment	1,322.87	1,418.54
(b) Capital Work-in-Progress	1,089.87	741.51
(c) Other Intangible Assets	4.21	3.93
(d) Biological Assets other than the Bearer Plants	0.56	2.90
(e) Financial Assets		
(i) Investments	-	-
(ii) Loans	-	-
(e) Financial Assets	41.14	52.37
(f) Other Non-current Assets	36.78	53.68
	2,495.44	2,272.93
(2) Current assets		
(a) Inventories	622.22	639.67
(b) Financial Assets		
(i) Trade Receivables	492.12	584.36
(ii) Cash and Cash Equivalents	212.69	235.31
(iii) Other Financial Assets	4.31	3.99
(iv) Loans	179.99	0.97
(c) Current Tax Assets	-	-
(c) Other Current Assets	103.72	128.81
	1,615.06	1,593.10
Total Assets	4,110.49	3,866.03
II. EQUITY AND LIABILITIES		
(1) Equity		
(a) Share capital	85.07	85.07
(b) Other equity	2,198.01	1,925.65
Equity Attributable to Owners	2,283.08	2,010.72
Non Controlling Interest	76.50	54.21
	2,359.58	2,064.93
(2) Liabilities		
(a) Non-current liabilities		
(i) Financial Liabilities		
-Borrowings	828.42	764.76
-Other Financial Liabilities	54.87	53.58
-Lease Liabilities	-	-
(ii) Deferred Tax Liabilities (Net)	72.76	88.17
(iii) Other non-current liabilities	181.20	59.93
	1,137.25	966.44
(b) Current liabilities		
(i) Financial Liabilities		
-Borrowings	32.79	325.42
-Trade Payables	280.86	200.23
-Other Financial Liabilities	198.87	136.17
-Lease Liabilities	-	-
(ii) Other Current Liabilities	26.36	168.26
(iii) Current Tax Liabilities (Net)	30.83	-
(iii) Provisions	43.95	4.56
	613.66	834.66
	1,750.91	1,801.10
Total Equity and Liabilities	4,110.49	3,866.03

STATEMENT OF AUDITED CONSOLIDATED CASH FLOWS FOR THE YEAR ENDED ON 31 MARCH 2021

Amount in INR Million

Particulars	Year Ended	
	31-03-2021	31-03-2020
	Audited	Audited
A. Cash Flow from Operating Activities		
Profit Before Tax	501.03	413.26
Adjustments For:		
Depreciation and Amortisation Expense	133.14	132.30
Exceptional Items	33.21	-
Loss on disposal of investment in subsidiary	-	0.74
Provision for doubtful debt	2.87	-
Bad Debts Written off	6.90	0.62
(Profit) / Loss on Sale of Property, Plant & Equipments	23.22	(5.31)
Interest expense	40.25	76.66
Interest Income	(12.94)	(3.73)
Operating Profit / (Loss) Before Changes in Working Capital	727.67	614.54
Adjustments For:		
Trade Receivables	82.47	(256.33)
Inventories	17.46	(131.82)
Other Assets	25.09	-
Other Non Current Assets	16.90	33.29
Trade Payables	80.63	98.63
Other Current Liabilities	(108.88)	96.07
Short-term Provisions	(4.10)	(3.33)
Loans	(179.03)	1.61
Other Financial Liability	63.98	29.60
Other Financial Assets	(2.42)	(5.18)
Cash Generated From Operations	719.75	477.09
Income Tax paid (net)	(139.36)	(109.36)
Net Cash Flow from Operating Activities (A)	580.39	367.73
B. Cash Flow from Investing Activities		
Proceeds from sale of Property, Plant & Equipment	0.42	9.81
Capital Expenditure on Property, Plant & Equipment	(407.42)	(734.98)
Interest received	12.67	3.73
Investment in Bank Deposits (net)	10.74	(23.30)
Net Cash Flow from / (used in) Investing Activities (B)	(383.58)	(744.73)

Particulars	Year Ended	
	31-03-2021	31-03-2020
	Audited	Audited
C. Cash Flow from Financing Activities		
Proceeds from long term borrowings	63.67	181.25
Proceeds from Issue of Share Capital in subsidiary entities from Non-controlling interest shareholders	19.64	-
Proceeds/(Repayment) of Short-term Borrowings (net)	(292.64)	100.44
Interest Paid	(40.25)	(76.66)
Proceeds from Grants	123.54	54.19
Dividend Paid (Including Dividend Distribution Tax)	(56.15)	(71.79)
Net Cash Flow from / (used in) Financing Activities (C)	(182.19)	187.43
Exchange rate fluctuation arising on consolidation (D)	(37.24)	18.42
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C+D)	(22.62)	(171.16)
Cash and Cash Equivalents at the beginning of the year	235.31	406.47
Cash and Cash Equivalents at the end of the year	212.69	235.31

Notes:

1. The above consolidated financial results of Hester Biosciences Limited (the "Company") and its subsidiaries (together referred as the "Group") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 8 June 2021.
2. Exceptional items includes loss on disposal of Patan farm aggregating to INR 33.21 million.
3. Followings are the details of segment wise revenue, results, segment assets and liabilities:

(Amount in INR Million)

Particulars	Quarter Ended			Year Ended	
	31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020
Segment Revenue					
a. Pou try Healthcare	527.00	395.83	302.22	1,564.51	1,203.46
b. Ani l Healthcare	114.75	173.11	133.99	578.81	629.22
Total	641.75	568.94	436.20	2,143.32	1,832.67
Segment Results					
a. Poultry Healthcare	168.48	101.03	59.92	389.11	309.40
b. Animal Healthcare	-12.51	90.80	61.81	180.92	126.03
Total	155.97	191.83	121.73	570.03	435.43
Finance Costs	14.35	15.23	33.05	66.04	81.34
Other unallocated expenditure/ (income) (net)	2.96	-	26.27	2.96	-59.17
Profit before Tax	138.66	176.60	62.41	501.03	413.26
Segment Assets					
a. Poultry Healthcare	1,891.35	1,925.30	2,117.64	1,891.35	2,117.64
b. Animal Healthcare	1,993.65	2,360.74	1,618.50	1,993.65	1,618.50
Unallocated Assets	225.49	659.10	129.89	225.49	129.89
Total	4,110.49	4,945.14	3,866.03	4,110.49	3,866.03
Segment Liabilities					
a. Poultry Healthcare	220.23	240.19	154.73	220.23	154.73
b. Animal Healthcare	309.87	660.36	321.36	309.87	321.36
Unallocated Liabilities	1,220.81	1,323.08	1,325.01	1,220.81	1,325.01
Total	1,750.91	2,223.63	1,801.10	1,750.91	1,801.10

4. The Board of Directors has recommended a dividend of INR 10 per equity share (100%) for FY21, subject to the approval of the shareholders in the ensuing Annual General Meeting.
5. The Code on Social Security, 2020 ("Code") relating to employees benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/ interpretation have not yet been issued. The Group will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.

6. The figures for the last quarters are the balancing figures between the audited figures in respect of the full year ending 31 March 2021 and 31 March 2020 and the unaudited published year-to-date figures up to 31 December 2020 and 31 December 2019 respectively, being the date of the end of the third quarter of the respective financial years which were subjected to limited review.
7. The figures for the previous year/periods have been regrouped/reclassified wherever necessary to make them comparable to current year/period.
8. Key numbers of the standalone financial results of the Company for the quarter and year ended on 31 March 2021 are as under:

Particulars	Amount in INR Million				
	Quarter Ended			Year Ended	
	31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020
Total Income	632.78	534.53	417.29	2,101.25	1,723.52
Profit Before Tax and Exceptional Items	178.17	178.45	65.01	600.60	412.29
Profit before tax	125.40	178.45	65.01	547.83	412.29
Profit After Tax	88.59	132.91	50.03	399.01	312.24
Total Comprehensive Income for the period	88.60	133.62	50.37	401.15	308.23

The Standalone Financial Results are available at the Company's website hester.in and on the website of the stock exchanges www.bseindia.com and www.nseindia.com.

For and on behalf of the Board of Directors



Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

Place: Ahmedabad
Date: 08.06.2021

Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cmshah@cmshah.com • Website : www.cmshah.com

Independent Auditor's Report on Quarterly and Year to date Audited Consolidated financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hester Biosciences Limited

Opinion

We have audited the accompanying statement of consolidated financial results of **Hester Biosciences Limited** ("the Holding company") and its subsidiaries (the Holding and its subsidiaries together referred to as "the Group") for the quarter and year ended 31st March, 2021 ("the Statement"), attached herewith, being submitted by the Holding company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of report of other auditors on separate audited financial statements/financial results/financial information of subsidiaries, the Statement:

i. includes the results of the following subsidiaries:

Sr. No.	Name of the Company
---------	---------------------

1	Texas Lifesciences Private Limited
2	Hester Biosciences Nepal Private Limited
3	Hester Biosciences Africa Limited
4	Hester Biosciences Kenya Limited
5	Hester Biosciences Tanzania Limited (Stepdown subsidiary)

- ii. is presented in accordance with the requirements of Regulation 33 of Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013, as amended ('the Act'). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our audit opinion.



Management's Responsibilities for the Consolidated Financial Results

The Statement have been prepared on the basis of the consolidated financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net consolidated profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the Companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the Companies included in the Group are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group are also responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions; misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the Group of which we are the independent auditors to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matter

- a. The accompanying Statement includes the audited financial results/statements and other financial information, in respect of the 4 subsidiaries and 1 stepdown subsidiary, whose financial statements/results reflect total assets of Rs. 1923.33 Mn as at 31st March, 2021 and total revenue of Rs. 103.95 Mn and Rs. 310.72 Mn, total net profit/(loss) after tax of Rs. 2.5 Mn and Rs. (34.27) Mn and total comprehensive income/(loss) of Rs. 3.56 Mn and Rs. (32.60) Mn for the quarter and the year ended on that date respectively, and net cash inflows of Rs. 16.83 Mn for the year ended 31st March, 2021, as considered in the Statement which have been audited by their respective independent auditors.

The independent auditors' reports on the financial statements/financial results/financial information of the above referred entities have been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of such auditors and the procedures performed by us as stated in paragraph above.

Our opinion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.



- b. The financial results include the results for the quarter ended March 31, 2021 being the balancing figures between the audited figures with respect to full financial year ended March 31, 2021 and the published unaudited year-to-date figures upto the end of the third quarter of the current financial year, which were subject to limited review by us, as required under the Listing Regulations.
- c. The comparative financial information of the Company for the corresponding quarter and year ended March 31, 2020, included in these standalone financial results, were audited by the predecessor auditor who expressed an unmodified opinion on those financial information on 26th June, 2020.

For, Chandulal M. Shah & Co.

Chartered Accountants

FRN 101698W

Arpit D. Shah

Arpit D. Shah

Partner

M. No. 135188

UDIN: 21135188AAAACQ5718

Date: 8th June 2021

Place: Ahmedabad



Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cmshah@cmshah.com • Website : www.cmshah.com

Independent Auditor's Report on Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hester Biosciences Limited

Opinion

We have audited the accompanying standalone financial results of **Hester Biosciences Limited** ('the Company') for the quarter and year ended March 31, 2021 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- is presented in accordance with the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013, as amended ('the Act'). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes



maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions; misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's



ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

1. The Statement includes the results for the quarter ended March 31, 2021 being the balancing figures between the audited figures with respect to full financial year ended March 31, 2021 and the published unaudited year-to-date figures upto the third quarter of the current financial year, which were subjected to limited review by us, as required under the Listing Regulations.
2. The comparative financial information of the Company for the corresponding quarter and year ended March 31, 2020, included in these standalone financial results, were audited by the predecessor auditor who expressed an unmodified opinion on those financial information on 26th June, 2020.

For, Chandulal M. Shah & Co.

Chartered Accountants

FRN 101698W



Arpit D. Shah

Partner

M. No. 135188

UDIN: 21135188AAAACP7004

Date: 8th June 2021

Place: Ahmedabad



Press Release

8 June 2021

Q4FY21 Sales up by 52%, FY21 Sales up by 23%

Q4FY21 Net Profit up by 77%, FY21 Net Profit up by 28%

Financial Highlights (Standalone)

INR in Million

Particulars	Q4			12 Months		
	FY21	FY20	Growth	FY21	FY20	Growth
Net Sales	631.58	414.32	52%	2084.77	1694.25	23%
Net Profit	88.59	50.03	77%	399.01	312.24	28%
EPS in INR	10.41	5.88	77%	46.90	36.70	28%

Division-wise sales in INR Million

Particulars	Q4			12 Months		
	FY21	FY20	Growth	FY21	FY20	Growth
Poultry Healthcare	476.21	302.55	57%	1513.97	1207.15	25%
Animal Healthcare	86.79	74.25	17%	395.07	333.08	19%
Other	68.58	37.52	83%	175.73	154.02	14%
TOTAL	631.58	414.32	52%	2084.77	1694.25	23%

Profitability Analysis

Particular	Q4FY21	Q4FY20	FY21	FY20
Gross Profit Margin	57.14%	65.71%	61.95%	66.97%
EBIDTA Margin	32.62%	24.78%	34.53%	31.12%
Net Profit Margin	14.03%	12.07%	19.14%	18.43%

Balance Sheet Analysis

Particular	Q4FY21	Q4FY20	Up/(Down)	FY21	FY20	Up/(Down)
ROE	14.92%	9.85%	5.07%	16.79%	15.37%	1.42%
ROCE	28.65%	12.98%	15.67%	25.90%	17.63%	8.27%
ROI	12.57%	7.22%	5.35%	14.15%	11.26%	2.89%

Business Overview of Hester India for FY21

Quantitative review

1. The year FY21 has been in line with the financial forecasts and the budgets. During FY21, the overall topline grew by 23% compared to the topline of FY20.
 - a. Domestic sales have registered a growth of 55% in Q4FY21 and 29% in FY21. There was a steep rise in local demand, mainly for the poultry vaccines and health products. Bird-flu incidences in the poultry led towards heavy usage of preventive and curative medication which led an increase in the demand.
 - b. Export sales have registered a marginal growth of 3% in Q4FY21 and a marginal degrowth of 4% in FY21. The main reason for the exports remaining flat in the year was a more or less stand-still in airlines cargo movement due to covid
2. While quarter to quarter gross margins have always been oscillating within a band, the overall year's EBITDA margins have improved.

Qualitative review

1. Rationalising of product mix continued during the year, besides adding newer products.
2. Marketing and administrative expenses continued to show a downward trend, thereby ensuring a healthier bottom line.

Dividend for the year FY21

The Board of directors has recommended a dividend of INR 10.00 per equity share (100%) for FY21, subject to the approval of the shareholders. This dividend recommendation is in line with the company's dividend policy to distribute a minimum of 18% of the PAT.

Going Further

1. Registration process continues for the Classical Swine Fever vaccine, Lumpy skin disease vaccine and Sheep Pox vaccine. We hope to commence the commercial production and marketing for all the three vaccines by December 2021.
2. The recently launched Herbal products division is expected to give substantial results in increasing the top-line this financial year.

The over-all poultry and animal health business of Hester is slated to grow at a faster rate than what it has been growing in the last few years. This growth will be due to increase the product range as well as due to adding geographical territories.

Status on Hester's initiatives in developing Covid-19 vaccine

Collaboration with IIT Guwahati

- On 15 April 2020, Hester signed an agreement with IITG to develop a vaccine against Covid-19.
- IITG is working towards developing the recombinant vaccine candidate, based on which, Hester shall take the project further from developing the master seed up to commercially manufacturing the vaccine.

MOU with Bharat Biotech

- On 27 May 2021, an MOU was signed between Bharat biotech and Gujarat Covid Vaccine Consortium (GCVC) of which Hester is a part.
- The MOU was towards contract manufacturing of the Drug Substance for Covaxin, for Bharat Biotech.
- Hester shall provide the complete infrastructure at its Gujarat plant for the manufacturing of the Drug Substance.
- The project is progressing as per the timeline.

Business Overview of Hester Nepal

FY21 has not been as per the expectations. Due to the pandemic, FAO tendering for PPR has been very low, notwithstanding the restrictions in air shipments for vaccines supplies, internationally.

Financials in INR Million

Particular	Q4FY21	Q4Y20	FY21	FY20
Net Sales	4.19	116.44	47.51	161.80
Net Profit / (Loss)	6.81	57.75	(9.73)	39.39

Business Overview of Texas Lifesciences

Texas Lifesciences has continued to show growth in the topline and profit. We are in process of expanding the capacity for Texas and making further improvements in the manufacturing process to increase the over-all efficiency.

Financials in INR Million

Particular	Q4FY21	Q4FY20	FY21	FY20
Net Sales	66.95	34.95	180.01	128.03
Net Profit / (Loss)	3.76	0.19	13.46	10.17

Business Overview of Hester Tanzania

Company is in process of establishing additional sales and distribution networks keeping in focus the demands from Tanzanian market as well as of the East African countries.

Financials in INR Million

Particular	Q4FY21	Q4FY20	FY21	FY20
Net Sales	8.70	6.17	40.88	27.03
Net Profit / (Loss)	(1.17)	(16.00)	(3.88)	(2.68)

Business Overview of Hester Africa

The project construction is near completion. The commercial production is expected to start by September 2021.



Rajiv Gandhi
Hester Biosciences Limited
CEO & Managing Director